Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SALL1 antisense RNA 1 (SALL1-AS1, also known as LOC105371256) is a long non-coding RNA classified as an antisense RNA, transcribed from the SALL1 gene locus, running in the opposite orientation to the SALL1 protein-coding transcript. Antisense lncRNAs often regulate their sense gene partners by recruiting chromatin-modifying complexes, influencing transcriptional activity, and modulating gene expression at the epigenetic level[2]. While many antisense lncRNAs are increasingly recognized for their ability to impact cancer progression and development in various tissues, no disease-specific role or direct associations with SALL1-AS1 have been established in current literature or databases. There are no known drugs targeting SALL1-AS1, and it is not currently considered a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SALL1 antisense RNA 1 (SALL1-AS1).